ImmuMap Services, a state-of-the-art flow cytometry services company, is proud to announce collaboration with Vaccibody, a leading cancer vaccine development company based in Oslo, Norway.
We are currently using multicolor flow cytometry to investigate the in vivo efficacy of Vaccibody’s personalized neoantigen cancer vaccine. We will continue testing samples for multiple antigen-specific T cell responses from the clinical trial VB C-01, in which patients with human papilloma virus (HPV) 16-induced cancer were vaccinated with Vaccibodies, an innovative DNA vaccine approach.
Using our multicolor flow cytometry expertise we will deliver high-quality data from which a decision can be taken.
We look forward to an extensive and rewarding relationship with Vaccibody.